Annexon Biosciences

About Annexon Biosciences

Annexon Biosciences is focused on developing transformative therapies by targeting C1q, the initiating molecule of the classical complement pathway, to stop devastating autoimmune, neurodegenerative, and ophthalmic diseases affecting the body, brain, and eye.

Products & Services

Complement Therapies:Next generation of early complement inhibitors targeting diseases of the body, brain, and eye by blocking damaging components of the immune system's classical complement pathway.

Specialties

Complement Therapies Autoimmune Diseases Neurodegenerative Diseases Ophthalmic Diseases C1q Targeting classical complement pathway inhibition autoimmune diseases neurodegenerative diseases ophthalmic diseases

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 86250000 MR: - FA: $86.25 million FAN: 86250000	D: 2025-11-14 FD: 2025-11-14	3 investors
2	RT: Public Offering of Common Stock and Pre-Funded Warrants T: - FT: Public Offering of Common Stock and Pre-Funded Warrants	A: 75000000 MR: - FA: $75 million FAN: 75000000	D: 2025-11-12 FD: 2025-11-12	3 investors
3	RT: Public Offering T: - FT: Public Offering	A: 75000000 MR: - FA: $75 million FAN: 75000000	D: 2025-11-12 FD: 2025-11-12	3 investors
4	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 125000000 MR: - FA: $125.0 million FAN: 125000000	D: 2024-06-05 FD: 2024-06-05	5 investors
5	RT: Public Offering T: - FT: Public Offering	A: 125000000 MR: - FA: $125 million FAN: 125000000	D: 2024-06-04 FD: 2024-06-04	5 investors
6	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 125000000 MR: - FA: $125.0 million FAN: 125000000	D: 2023-12-20 FD: 2023-12-20	2 investors

Public Offering Latest

2025-11-14

$86.2M

3 investors (Pro only)

Public Offering of Common Stock and Pre-Funded Warrants 2025-11-12

$75.0M

Public Offering 2025-11-12

$75.0M

View 5 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

B

Ben Barres

SCIENTIFIC CO-FOUNDER

A

Arnon Rosenthal

SCIENTIFIC CO-FOUNDER

D

Douglas Love

PRESIDENT & CHIEF EXECUTIVE OFFICER

T

Ted Yednock

EVP & CHIEF INNOVATION OFFICER

J

Jamie Dananberg

EVP & CHIEF MEDICAL OFFICER

R

Rick Artis

CHIEF SCIENTIFIC OFFICER

View 19 more team members with Pro

Unlock Full Team Directory

Recent News